A New Outcomes-Based Payment Plan From a Chinese Company to Improve Patient Affordability of CAR-T Product

Document Type : Letter to Editor

Authors

1 Department of Pharmacy, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

2 Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China

Keywords

Full Text

Dear Editor,


Chimeric antigen receptor (CAR)-T cell immunotherapy is rapidly transforming the landscape of cancer care, producing significantly good remission rates in patients with hematological cancers.1 Despite the remarkable outcomes in clinical trials, many patients cannot access this treatment due to high costs.2 This results in patients out of reach of desired medications (CAR-T drugs) and companies incurring revenue deficit, significantly curbing the positive social effects of the innovative drugs. ...(Read more...)

References

  1. Elsallab M, Levine BL, Wayne AS, Abou-El-Enein M. CAR T-cell product performance in haematological malignancies before and after marketing authorisation. Lancet Oncol. 2020;21(2):e104-e116. doi:1016/s1470-2045(19)30729-6
  2. Kilgour MK, Bastin DJ, Lee SH, Ardolino M, McComb S, Visram A. Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy. Front Immunol. 2023;14:1166038. doi:3389/fimmu.2023.1166038
  3. Cao X, Li W, Yu Y, Liu T, Zhou Y. China enters CAR-T cell therapy era. Innovation (Camb). 2022;3(1):100197. doi:1016/j.xinn.2021.100197
  4. Sina Net. The Million Anticancer CAR-T Drug Reduces Price in Disguise: To Be Paid Based on Outcomes, with the Highest Refund of Up to 600,000 RMB. January 17, 2024. https://finance.sina.cn/cj/2024-01-17/detail-inacviah2922534.d.html.
  5. National Medical Products Administration. Searching Results of NMPA Approved CAR-T Drugs. July 9, 2024. https://www.nmpa.gov.cn/datasearch/search-result.html.
  6. Fiorenza S, Ritchie DS, Ramsey SD, Turtle CJ, Roth JA. Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transplant. 2020;55(9):1706-1715. doi:1038/s41409-020-0956-8
  7. Jørgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. J Mark Access Health Policy. 2020;8(1):1715536. doi:1080/20016689.2020.1715536
  8. Jørgensen J, Kefalas P. The use of innovative payment mechanisms for gene therapies in Europe and the USA. Regen Med. 2021;16(4):405-422. doi:2217/rme-2020-0169
  9. Sun W, Liang AB, Huang H, Huang XJ. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience. Haematologica. 2023;108(8):2011-2028. doi:3324/haematol.2022.282316
  10. Lambert P, Perelman S, Pestieau P, Schoenmaeckers J. Health insurance coverage and adverse selection. In: Börsch-Supan A, Brandt M, Hank K, Schröder M, eds. The Individual and the Welfare State: Life Histories in Europe. Berlin, Heidelberg: Springer; 2011:225-231. doi:1007/978-3-642-17472-8_20
  11. Rothschild M, Stiglitz J. Equilibrium in competitive insurance markets: an essay on the economics of imperfect information. Q J Econ. 1976;90(4):629-649. doi:2307/1885326
  12. Thomasson MA. Early evidence of an adverse selection death spiral? The case of Blue Cross and Blue Shield. Explor Econ Hist. 2004;41(4):313-328. doi:1016/j.eeh.2004.02.001

Files

History

  • Receive Date: 17 April 2024
  • Revise Date: 11 July 2024
  • Accept Date: 02 August 2024
  • First Publish Date: 04 August 2024

Share

How to cite

Statistics